ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1788

Pulmonary Vascular Dysfunction Occurs in Association with Hyperuricaemia: Assessment by a Novel Non-Invasive Measurement of Pulmonary Pulse Wave Transit Time

Rachael Flood1, Nicole Fagan2, Diarmuid O'Brien1, Colm Kirby1, David Kane1 and Ronan Mullan1, 1Tallaght University Hospital, Dublin, Ireland, 2St James' Hospital, Dublin, Ireland

Meeting: ACR Convergence 2022

Keywords: gout, hyperuricemia, pulmonary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Hyperuricaemia is common in pulmonary hypertension (PH) occurring in up to 80% of patients with serum uric acid levels(sUA) correlating with poor PH outcomes. sUA through its role in nitric oxide inhibition and endothelial dysfunction has been suggested as a potential mediator of PH. Right heart catheterization (RHC) is the diagnostic gold-standard in PH, however by virtue of its invasive nature other methods are required. Pulmonary Pulse Wave Transit Time (pPTT) is a novel, validated echocardiographic measurement of increased pulmonary vascular tone in PH, defined as the delay between onset of ventricular electrical activity and the arrival of the pulse wave in the pulmonary vein by Doppler echocardiography. pPTT is shortened in PH. Following validation of pPTT in patients with confirmed PH, we assessed pPTT in a gout cohort before and after urate lowering therapy.

Methods: Patients with PH confirmed at right heart catheterisation versus matched controls were recruited and consented for baseline anthropomorphic assessment and focused echocardiograms. pPTT was calculated as the time interval between the R-wave on the ecg and the corresponding onset of RVOT pulse Doppler flow velocity (R-RVOT) minus the time between the R-wave on the ecg and the corresponding peak late-systolic pulmonary vein flow velocity (R- PVs2) normalized to cardiac cycle length. Treatment naïve hyperuricaemic ( >420umol/L Men. >360umol/L Women.) gout cases vs normouricaemic controls were recruited, with repeat assessments after a 3 month period of sUA within target range following treatment with urate lowering therapy for gout.

Results: R-PVs2 was reduced in PH cases(mean ± SE)(N=10. 167.40msec ±10.5) versus controls(N=13. 208.95msec ±17.01,P< 0.05.) pPTT was reduced in PH cases (0.104 ±0.01) versus controls (0.168±0.02,P< 0.01). R-PVs2 was reduced in hyperuricaemic gout cases (N= 22 176.63msec ± 11.6) versus controls(N=15 200.75msec ±15.73 P= 0.20) There was a significant reduction in pPTT in hyperuricaemic gout cases (0.12 ± 0.02) versus controls (0.16 ±0.01,P< 0.05.) pPTT was reassessed in 13 cases following a period of 3 months of normal sUA levels. sUA level was reduced (umol/L) between baseline(487.15 ±24.15) and 3 months (309.38 ±20.78 P=< 0.01). There was a non-significant increase in mean R-PVs2 from baseline(159.42ms ±14.37) and three months(168.84ms ±10.94) and non- significant increase in mean pPTT from baseline(0.09 ±0.02) following 3 months(0.12 ±0.02)

Conclusion: pPTT is a novel non invasive method of accessing pulmonary haemodynamics. Patients with hyperuricaemia have shortened pPTT indicative of pulmonary vascular dysfunction.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: R. Flood, None; N. Fagan, None; D. O'Brien, None; C. Kirby, None; D. Kane, AbbVie/Abbott; R. Mullan, None.

To cite this abstract in AMA style:

Flood R, Fagan N, O'Brien D, Kirby C, Kane D, Mullan R. Pulmonary Vascular Dysfunction Occurs in Association with Hyperuricaemia: Assessment by a Novel Non-Invasive Measurement of Pulmonary Pulse Wave Transit Time [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/pulmonary-vascular-dysfunction-occurs-in-association-with-hyperuricaemia-assessment-by-a-novel-non-invasive-measurement-of-pulmonary-pulse-wave-transit-time/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pulmonary-vascular-dysfunction-occurs-in-association-with-hyperuricaemia-assessment-by-a-novel-non-invasive-measurement-of-pulmonary-pulse-wave-transit-time/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology